The Combination of a BCL-xL PROTAC and an mTOR Inhibitor Sensitizes Pancreatic Ductal Adenocarcinoma to KRASG12D Inhibitor Treatment
Collectively, our findings suggest that the combination of DT2216/everolimus potentiates the anti-tumor efficacy of MRTX1133 associated with enhanced apoptosis induction and inhibition of compensatory survival signaling.
Authors
- Peiyi Zhang
- S. Khan
- Javed Miyan
- Vignesh Vudatha (ORCID: https://orcid.org/0000-0002-3624-3771)
- Daohong Zhou
- Lin Cao
- Lei Zheng
- Guangrong Zheng
- Jose Trevino
Institutions
- The University of Texas at San Antonio Health Science Center (US)
- Virginia Commonwealth University (US)
- University of Florida (US)
- The University of Texas at San Antonio (US)
Publication Details
- Journal
- Cancers
- Published
- 2026-03-12
- DOI
- https://doi.org/10.3390/cancers18060920
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health